Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1974 Jan 1;139(1):44–57. doi: 10.1084/jem.139.1.44

THE ROLE OF PROPERDIN IN THE ALTERNATE PATHWAY OF COMPLEMENT ACTIVATION

Otto Götze 1, Hans J Müller-Eberhard 1
PMCID: PMC2139515  PMID: 4808709

Abstract

Properdin (P), a highly basic euglobulin, was purified from human serum to molecular homogeneity without the use of zymosan. Isolated P was found to efficiently initiate activation of the alternate pathway of complement activation (C3 activator or properdin system) and to be an essential component during its early reaction stages. The activity of isolated P did not require the presence of an activating polysaccharide. It was therefore concluded that purified P had been obtained in an activated form (P). In an isolated reaction system containing purified C3, C3 proactivator (C3PA), and C3 proactivator convertase (C3PAse), P was able to mediate the activation of C3PAse which in turn activated C3PA to cleave C3. This activation of C3PAse was found to depend on the presence of native C3. These results allowed the formulation of a concept in which P is envisaged to act as a modulator of native C3 enabling it to activate C3PAse. Activation of C3 was efficiently mediated by P in the fluid phase. Efficient activation of C5, however, required the participation of an insoluble polysaccharide (zymosan). The possibility is raised therefore that P might also be an integral part of the multimolecular C5 convertase of the alternate pathway of complement activation.

Full Text

The Full Text of this article is available as a PDF (752.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avrameas S., Ternynck T. Biologically active water-insoluble protein polymers. I. Their use for isolation of antigens and antibodies. J Biol Chem. 1967 Apr 10;242(7):1651–1659. [PubMed] [Google Scholar]
  2. BLUM L., PILLEMER L., LEPOW I. H. The properdin system and immunity. XIII. Assay and properties of a heat-labile serum factor (factor B) in the properdin system. Z Immun exp ther. 1959 Oct-Nov;118:349–357. [PubMed] [Google Scholar]
  3. Bokisch V. A., Müller-Eberhard H. J., Cochrane C. G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969 May 1;129(5):1109–1130. doi: 10.1084/jem.129.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Calcott M. A., Müller-Eberhard H. J. C1q protein of human complement. Biochemistry. 1972 Aug 29;11(18):3443–3450. doi: 10.1021/bi00768a018. [DOI] [PubMed] [Google Scholar]
  5. Cooper N. R., Müller-Eberhard H. J. The reaction mechanism of human C5 in immune hemolysis. J Exp Med. 1970 Oct 1;132(4):775–793. doi: 10.1084/jem.132.4.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cooper N. R., Polley M. J., Müller-Eberhard H. J. The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry. 1970 Apr;7(4):341–356. doi: 10.1016/0019-2791(70)90237-5. [DOI] [PubMed] [Google Scholar]
  7. Ensky J., Hinz C. F., Jr, Todd E. W., Wedgwood R. J., Boyer J. T., Lepow I. H. Properties of highly purified human properdin. J Immunol. 1968 Jan;100(1):142–158. [PubMed] [Google Scholar]
  8. Goodkofsky I., Lepow I. H. Functional relationship of factor B in the properdin system to C3 proactivator of human serum. J Immunol. 1971 Oct;107(4):1200–1204. [PubMed] [Google Scholar]
  9. Götze O., Müller-Eberhard H. J. Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med. 1972 Jan 27;286(4):180–184. doi: 10.1056/NEJM197201272860403. [DOI] [PubMed] [Google Scholar]
  10. HINZ C. F., Jr, JORDAN W. S., Jr, PILLEMER L. The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1956 May;35(5):453–457. doi: 10.1172/JCI103296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. LEPOW I. H., PILLEMER L., SCHOENBERG M. D., TODD E. W., WEDGWOOD R. J. The properdin system and immunity. X. Characterization of partially purified human properdin. J Immunol. 1959 Oct;83:428–436. [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Minta J. O., Goodkofsky I., Lepow I. H. Solid phase radioimmunoassay of properdin. Immunochemistry. 1973 May;10(5):341–350. doi: 10.1016/0019-2791(73)90082-7. [DOI] [PubMed] [Google Scholar]
  14. Müller-Eberhard H. J., Fjellström K. E. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol. 1971 Dec;107(6):1666–1672. [PubMed] [Google Scholar]
  15. Müller-Eberhard H. J., Götze O. C3 proactivator convertase and its mode of action. J Exp Med. 1972 Apr 1;135(4):1003–1008. doi: 10.1084/jem.135.4.1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nicol P. A., Lachmann P. J. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology. 1973 Feb;24(2):259–275. [PMC free article] [PubMed] [Google Scholar]
  18. PENSKY J., WURZ L., PILLEMER L., LEPOW I. H. The properdin system and immunity. XII. Assay, properties and partial purification of a hydrazine-sensitive serum factor (factor A) in the properdin system. Z Immun exp ther. 1959 Oct-Nov;118:329–348. [PubMed] [Google Scholar]
  19. PILLEMER L., BLUM L., LEPOW I. H., ROSS O. A., TODD E. W., WARDLAW A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. doi: 10.1126/science.120.3112.279. [DOI] [PubMed] [Google Scholar]
  20. PILLEMER L., BLUM L., LEPOW I. H., WURZ L., TODD E. W. The properdin system and immunity. III. The zymosan assay of properdin. J Exp Med. 1956 Jan 1;103(1):1–13. doi: 10.1084/jem.103.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tamura H., Ui N. A new buffer system for disc electrophoresis suitable for slightly basic proteins. J Biochem. 1972 Mar;71(3):543–545. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES